Bottom line
SWISX vs IDEV: the short answer
SWISX (Schwab International Index Fund) and IDEV (iShares Core MSCI International Developed Markets ETF) share a meaningful slice of their top holdings — about 75% by weight.
But IDEV is far broader, holding 2,337 positions to 697 for SWISX, so beyond the top names it adds exposure SWISX doesn't have.
IDEV is cheaper at 0.04% vs 0.06% — a difference of $2.00 a year per $10,000 invested.
Over five years, SWISX returned +9.0% a year vs +5.0% for IDEV (reporting dates differ).
Updated Nov 19, 2026
SWISX vs IDEV side by side
| SWISX | IDEV | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Schwab | iShares |
| Category | International Stock | International Stock |
| Expense ratio | 0.06% | 0.04% |
| Annual cost per $10k | $6 | $4 |
| 10-yr cost on $10k (prospectus) | $77 | $51 |
| Max front load | — | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +31.6% | +4.5% |
| 5-yr return (annualized) | +9.0% | +5.0% |
| 10-yr return (annualized) | +8.3% | — |
| Best quarter | +18.2% | +16.9% |
| Worst quarter | −23.2% | −24.0% |
| Net assets (fund) | $13.6B | $31.6B |
| Number of holdings | 697 | 2,337 |
| Portfolio turnover | 1% | 3% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | SWISX | IDEV | Difference |
|---|---|---|---|
| 2024 | +3.5% | +4.5% | −1.0% |
| 2023 | +18.2% | +17.3% | +0.9% |
| 2022 | −14.3% | −14.9% | +0.7% |
| 2021 | +11.3% | +12.7% | −1.4% |
| 2020 | +8.1% | +8.4% | −0.3% |
| 2019 | +21.9% | +23.4% | −1.5% |
| 2018 | −13.3% | −14.3% | +1.0% |
Source: Fund prospectus bar charts
Holdings overlap
17 of SWISX's top 25 holdings also appear in IDEV's top 25.
| Holding | SWISX | IDEV |
|---|---|---|
| ASML Holding NV | 2.58% | 2.19% |
| Roche Holding AG | 1.48% | 1.05% |
| HSBC Holdings PLC | 1.41% | 1.24% |
| AstraZeneca PLC | 1.34% | 0.88% |
| Novartis AG | 1.30% | 0.98% |
| Nestle SA | 1.14% | 0.88% |
| Shell PLC | 1.03% | 0.88% |
| Sap Se | 0.96% | 0.65% |
| Mitsubishi UFJ Financial Group Inc | 0.96% | 0.82% |
| Banco Santander SA | 0.88% | 0.70% |
| Commonwealth Bank of Australia | 0.80% | 0.72% |
| Allianz SE | 0.79% | 0.65% |
| Schneider Electric SE | 0.73% | 0.63% |
| UBS Group AG | 0.70% | 0.57% |
| Banco Bilbao Vizcaya Argentaria SA | 0.68% | 0.54% |
Source: SEC Form N-PORT
SWISX top 10
- ASML Holding NV — 2.58%
- Roche Holding AG — 1.48%
- HSBC Holdings PLC — 1.41%
- AstraZeneca PLC — 1.34%
- Novartis AG — 1.30%
- Nestle SA — 1.14%
- Siemens AG — 1.06%
- Shell PLC — 1.03%
- Toyota Motor Corp — 0.99%
- Sap Se — 0.96%
IDEV top 10
- ASML Holding N.V. — 2.19%
- Hsbc Holdings Plc — 1.24%
- BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares — 1.16%
- Roche Holding AG — 1.05%
- Royal Bank Of Canada — 1.00%
- Novartis AG — 0.98%
- Astrazeneca Plc — 0.88%
- Nestle S.A. — 0.88%
- Shell Plc — 0.88%
- Siemens Aktiengesellschaft — 0.83%
FAQ
What is the difference between SWISX and IDEV?
Which is cheaper, SWISX or IDEV?
Should I own both SWISX and IDEV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.